Stemedica Receives a Patent for Stem Cell Testing

By Stemedica

Stemedica Cell Technologies, a manufacturer of allogeneic adult stem cells, has developed a technology for producing ischemic-tolerant cells, which researchers can use in clinical and pre-clinical trials. Stemedica recently received a U.S. patent for identifying neuripotent stem cells, or stem cells that have the capacity to become functioning brain cells.

Introduction

In February of 2014, Stemedica Cell Technologies announced the receipt of U.S. Patent No. 8,642,286 B2. This patent refers to the company's self-developed method for assessing the potency and viability of a neural cell population by engrafting the cells in question in a chick embryo's developing brain. Company executives stress the efficiency of this process in identifying cells that have the ability to differentiate and become functioning neural cells when introduced to the human brain.

About Stemedica

This testing procedure stands out as a promising development in the treatment of neurodegenerative diseases, which have in general responded well to propagated neural stem cells. The primary roadblock to these treatments, however, has been the failure of introduced cells to differentiate and become glial and neural cell lineages within the brain. By identifying cells' potential prior to introduction, scientists may be able to improve patient success rates.

Conclusion